logo-loader
TyraTech, Inc.

Fresh start for Tyratech with new strategic focus on animal health

Bruno Jactel, chief executive of Tyratech Inc. (LON:TYR LON:TYRU) chats to Proactive's Andrew Scott about the proposed sale of Vamousse to Alliance Pharma plc (AIM: APH).

It's for an initial cash consideration of $13mln with Tyratech potentially being entitled to further performance-based payments of up to $4.5 million.

Jactel also outlines their new strategic focus on animal health and the plans they've got to maximise opportunities in what's a $6bln market.

Quick facts: TyraTech, Inc.

Price: £0.00

Market: AIM
Market Cap: £0.00
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Brickability Group PLC looks to raise £57mln as it lists in London

Brickability Group PLC's chairman John Richards chats to Proactive's Andrew Scott ahead of the firm's listing next week in London. It plans to raise £57mln as part of the initial public offering, valuing it at around £150mln. The Bridgend-based company, which counts Redrow plc (LON:RRW)...

11 hours, 33 minutes ago

2 min read